deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02759588

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Phase 1b & 2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (VIRO-15)

Sponsor: Genelux Corporation

Conditions Fallopian Tube Cancer Ovarian Cancer Peritoneal Carcinomatosis
Interventions GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab
Updated 16 times since 2017 Last updated: Jan 3, 2023 Started: May 31, 2016 Primary completion: Dec 31, 2021 Completion: Dec 31, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02759588, this PHASE1/PHASE2 trial focuses on Fallopian Tube Cancer and Ovarian Cancer and remains completed. Sponsored by Genelux Corporation, it has been updated 16 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Jan 2018 · 4 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Dec 2018 · 3 months · monthly snapshot~Dec 2018 – ~Feb 2020 · 14 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2022 · 14 months · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Feb 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  4. Sep 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. May 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 11 earlier versions

  1. Apr 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Feb 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1_PHASE2

  4. Feb 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  5. Dec 2018 — Feb 2020 [monthly]

    Recruiting PHASE1_PHASE2

  6. Sep 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jan 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  9. Sep 2017 — Jan 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Phase: PHASE1 → PHASE1_PHASE2

  10. Feb 2017 — Sep 2017 [monthly]

    Recruiting PHASE1

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genelux Corporation
Data source: Genelux Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations